Brogden R N, Heel R C, Pakes G E, Speight T M, Avery G S
Drugs. 1979 Nov;18(5):329-53. doi: 10.2165/00003495-197918050-00001.
Glipizide is a 'second generation' oral hypoglycaemic agent similar in potency to glibenclamide. It is completely absorbed after oral administration and has a rapid onset of action, but the duration of its hypoglycaemic effect is shorter than that of glibenclamide. It is rapidly metabolised to inactive metabolites which are excreted in the urine. Therapeutic trials have shown the efficacy of glipizide in maturity onset diabetes mellitus to be comparable with that of glibenclamide and chlorpropamide in newly diagnosed patients unresponsive to diet as well as in patients previously treated with oral hypoglycaemic drugs. Glipizide is well tolerated, but careful adjustment of dosage and attention to diet may be needed to avoid hypoglycaemic symptoms a few hours after a single daily dose.
格列吡嗪是一种“第二代”口服降糖药,其效力与格列本脲相似。口服给药后可被完全吸收,起效迅速,但降糖作用持续时间比格列本脲短。它迅速代谢为无活性的代谢产物并经尿液排出。治疗试验表明,在新诊断的、饮食控制无效的成年型糖尿病患者以及先前接受口服降糖药治疗的患者中,格列吡嗪的疗效与格列本脲和氯磺丙脲相当。格列吡嗪耐受性良好,但可能需要仔细调整剂量并注意饮食,以避免每日单次给药后数小时出现低血糖症状。